Entera Bio Ltd. (ENTX)

In April 2026, Entera Bio announced the pricing of a $10.0 million direct investment by BVF Partners, with the potential for up to $24.5 million in total proceeds if warrants are exercised, to support the initiation of its Phase 3 study of EB613. In March 2026, the company announced its full-year 2025 financial results and submitted a streamlined Phase 3 protocol to the FDA for EB613. In February 2026, the company announced open market purchases of company stock by board members. In July 2025, the FDA agreed with Entera Bio's proposal for a single multinational Phase 3 study for EB613, with change in total hip bone mineral density as the primary endpoint.

There is no indication of significant demand seasonality for Entera Bio Ltd.'s products or services, as the demand for treatments for conditions like osteoporosis and hypoparathyroidism is generally consistent throughout the year.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing orally delivered large molecule therapeutics, including peptides and therapeutic proteins, operating within the Healthcare sector, specifically in the Biotechnology industry. The company's pipeline is built on its proprietary N-Tab™ oral peptide platform, which aims to convert injectable biologic drugs into oral tablet formats. Its major product candidates include EB613, an oral treatment for postmenopausal women with low bone mineral density; EB612, an oral peptide replacement therapy for patients with hypoparathyroidism; EB618, being developed as an oral dual GLP-1/glucagon tablet for obesity and metabolic diseases; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome, developed in collaboration with OPKO Health.

Entera Bio Ltd. is headquartered in Jerusalem, Israel, and its operations are based there.

Entera Bio's brand reputation is shaped by its scientific advancements and strategic collaborations. The company is recognized as a leader in developing orally delivered macromolecules and for its proprietary N-Tab™ oral peptide platform. Positive corporate developments, such as the FDA's alignment on the EB613 Phase 3 study design and the expanded collaboration with OPKO Health, have contributed positively to its standing. Analysts have provided a "Strong Buy" consensus rating with a significant upside potential, although some AI analyst ratings suggest a "Neutral" outlook due to financial performance.

Individual investors hold a substantial 55% stake in Entera Bio Ltd. Major institutional owners and shareholders include Knoll Capital Management, LLC, Point72 Asset Management, L.P., Marshall Wace, Llp, Schonfeld Strategic Advisors LLC, Parkman Healthcare Partners LLC, Northern Trust Corp, Seven Fleet Capital Management LP, Renaissance Technologies Llc, Jane Street Group, Llc, Susquehanna International Group, Llp, and OPKO Health, Inc. As of April 10, 2026, 14.11% of Entera Bio's stock is owned by institutional investors.